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ARTICLE
Adoptive cancer immunotherapy using DNA-
demethylated T helper cells as antigen-presenting
cells
Alexei F. Kirkin1,2, Karine N. Dzhandzhugazyan1,2, Per Guldberg 1, Johnny Jon Fang1,2, Rikke S. Andersen 3,
Christina Dahl 1, Jann Mortensen 4, Tim Lundby4, Aase Wagner5, Ian Law4, Helle Broholm6, Line Madsen7,
Christer Lundell-Ek 2, Morten F. Gjerstorff 3, Henrik J. Ditzel 3,8, Martin R. Jensen2 & Walter Fischer2,9
In cancer cells, cancer/testis (CT) antigens become epigenetically derepressed through DNA
demethylation and constitute attractive targets for cancer immunotherapy. Here we report
that activated CD4+ T helper cells treated with a DNA-demethylating agent express a broad
repertoire of endogenous CT antigens and can be used as antigen-presenting cells to gen-
erate autologous cytotoxic T lymphocytes (CTLs) and natural killer cells. In vitro, activated
CTLs induce HLA-restricted lysis of tumor cells of different histological types, as well as cells
expressing single CT antigens. In a phase 1 trial of 25 patients with recurrent glioblastoma
multiforme, cytotoxic lymphocytes homed to the tumor, with tumor regression ongoing in
three patients for 14, 22, and 27 months, respectively. No treatment-related adverse effects
were observed. This proof-of-principle study shows that tumor-reactive effector cells can be
generated ex vivo by exposure to antigens induced by DNA demethylation, providing a novel,
minimally invasive therapeutic strategy for treating cancer.
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Adoptive transfer of naturally occurring or geneticallyengineered immune effector cells has demonstratedtherapeutic beneﬁt in clinical trials of advanced
cancers1, 2. One successful approach is the adoptive transfer of
autologous tumor-inﬁltrating lymphocytes (TILs) in melanoma
patients resulting in complete response rates of up to 40%3.
Alternative approaches utilize T cells genetically engineered to
confer speciﬁcity for tumor-associated antigens by introducing a
cloned T cell receptor (TCR) or a chimeric antigen receptor
(CAR)2. Early phase clinical trials of these strategies have yielded
promising results in the treatment of melanoma and other
cancers4, 5.
A critical determinant of tumor eradication by adoptive
immunotherapy is the tumor-associated antigen(s) recognized by
cytotoxic T lymphocytes (CTLs). One major class of cancer
rejection antigens encompasses neoantigens, which arise through
tumor-speciﬁc DNA alterations that lead to the generation of
aberrant proteins6. Neoantigens usually differ from patient to
patient, and are thought to be the major targets in TIL-based
therapies and therapies aiming at nonspeciﬁc immune activation
through inhibition of T cell checkpoint proteins, such as CTLA-4
and PD-1. The second major class of cancer rejection antigens
encompasses cancer/testis (CT) antigens (also known as cancer
germline antigens), a heterogeneous group of >100 proteins of
different families with largely unknown functions7. CT antigens
are repressed in normal adult tissues, with the exception of non-
major histocompatibility complex (MHC)-expressing germ cells,
but are aberrantly re-expressed in most human cancers due to
promoter demethylation7, 8. Clinical trials utilizing T cells
genetically engineered to recognize single CT antigens, such as
MAGE-A3 or CTAG1 (also known as NY-ESO-1), have shown
high response rates for selected patient groups4, 9, but this
approach generally has limitations due to extensive interpatient
and intratumor heterogeneity of CT-antigen expression7.
Herein we describe an autologous procedure developed to
induce an immune response against a broad repertoire of CT
antigens, the key elements of which are (1) generation of pro-
liferating activated CD4+ T “helper” (TH) cells by incubation of
normal peripheral blood lymphocytes (PBLs) with fully mature
dendritic cells (DCs); (2) induction of endogenous CT-antigen
expression in activated TH cells by treatment with a DNA-
demethylating agent, and (3) ex vivo immunization of normal
lymphocytes using demethylated TH cells as antigen-presenting
cells. The CTLs and natural killer (NK) cells generated by this
procedure exhibit early differentiation phenotypes, both expres-
sing CD62L (also known as L-selectin), and can potentially be
used for treatment of a broad range of advanced human cancers.
We have tested this approach in a phase 1 clinical trial
(NCT01588769) of patients with late-stage recurrent glioblastoma
multiforme (GBM), a highly malignant primary brain tumor
usually associated with a rapidly fatal clinical course10, 11.
Results
Generation of TH cell-enriched lymphocyte populations. Gene
repression by DNA cytosine methylation may be reversed by the
action of nucleoside-based inhibitors of DNA methyltransferase.
However, as DNA replication is required for this process12, drug-
induced demethylation is not feasible in non-dividing antigen-
presenting cells such as DCs. Instead, we focused our work on TH
cells, which also can function as antigen-presenting cells for
generation of autologous CTLs13. Proliferation of isolated TH cells
can be effectively stimulated by incubation with phytohe-
magglutinin (PHA)13 or a combination of antibodies against CD3
and CD2814. However, to avoid the possible adverse effects
associated with the use of foreign proteins for immunization
procedures15, we exploited our initial observation that co-
culturing unseparated PBLs with autologous fully mature
antigen-unloaded DCs induced intense lymphocyte proliferation
and enrichment of TH cells (Fig. 1).
The DCs used for this activation and enrichment procedure
were matured in medium containing IL-1β, IL-6, TNF-α, and
PGE2. They expressed high levels of CD40, CD80, and CD86
(Fig. 1a) and, during maturation, released the Th1-polarizing
cytokine, IL-12p70 (200.6 ± 84.1 pg/106 cells; seven independent
cultures). Incubation of DCs with autologous lymphocytes in the
presence of low concentrations of IL-2 (25 IU/ml) resulted in
intensive cell proliferation after ~7 days (Fig. 1b). The most
rapidly proliferating were CD4+ cells, which constituted ~50% in
the parental cultures and >80% in the DC-induced cultures
(Fig. 1c). Interestingly, these CD4+ cells were highly positive for
HLA class II, CD80 and CD86, all markers of professional
antigen-presenting cells16, and also expressed CD70, a ligand for
CD27 and marker of Th1 helper cells17 (Fig. 1d). There was only
minimal expression of stress-associated molecules (Supplemen-
tary Fig. 1). Of note, no proliferation of lymphocyte cultures was
observed in the absence of DCs, even in the presence of IL-2
(Fig. 1b). In contrast to stimulation with DCs, treatment of PBLs
with PHA did not induce preferential proliferation of CD4+ cells
(Supplementary Table 1).
Epigenetic derepression of CT antigens. Having established
conditions for generating lymphocyte cultures enriched for pro-
liferating TH cells, we next attempted to induce expression of
endogenous CT antigens in these cells by epigenetic manipula-
tion. In cancer cell lines, derepression of genes silenced by pro-
moter hypermethylation, including CT antigens18, can be readily
induced in vitro by treatment with demethylating agents such as
5-aza-2′-deoxycytidine (5-aza-CdR). Although it has proven
considerably more difﬁcult to induce a state of DNA demethy-
lation in normal human cells18, a few studies have demonstrated
5-aza-CdR-induced re-expression of some MAGE antigens in
primary ﬁbroblasts and PHA-activated lymphocytes19, 20.
To investigate whether CT antigens can be derepressed in DC-
induced lymphocytes, we tested a number of 5-aza-CdR
concentrations, culture conditions and incubation times. Robust
and consistent expression of selected CT antigens representing
different families (MAGE, GAGE, CTCFL, and CTAG1) was
achieved by treating cells in logarithmic growth phase with 10 µM
5-aza-CdR for 2–3 days in the presence of IL-2 (150 IU/ml). The
phenotype of 5-aza-CdR-treated cells was similar to that of
untreated cells (Fig. 2a, b), and only a slight induction in the
expression of the stress proteins MICA/MICB was observed
(Supplementary Fig. 1). Reverse transcription polymerase chain
reaction (RT-PCR) analysis of selected CT antigens showed
complete lack of expression in untreated lymphocytes, but clear
induction of expression in 5-aza-CdR-treated cells (Fig. 2c and
Supplementary Figs. 2 and 3). After termination of 5-aza-CdR
treatment, expression of CT antigens remained stable for at least
3 days (Supplementary Fig. 4). Analysis of separated CD4+ and
CD8+ T-cell populations showed that expression of CT antigens
was induced by 5-aza-CdR in both cell types at comparable levels
(Supplementary Fig. 5).
MAGE expression was also demonstrated at the protein level
using the antibody 57B, which recognizes an epitope common to
several MAGE antigens21. The speciﬁcity of the 57B antibody was
conﬁrmed by sandwich ELISA (Supplementary Fig. 6). Consistent
with the data on mRNA expression, MAGE proteins were clearly
detectable in 5-aza-CdR-treated lymphocytes by immunoblotting
(Fig. 2d and Supplementary Fig. 7) and cell-based ELISA (Fig. 2e),
albeit at lower levels than in MDA-MB-231 breast cancer cells.
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Changes in DNA methylation were evaluated in lymphocytes
after 1–3 days of 5-aza-CdR treatment. Quantitative analysis of
the methylation status of CpG sites in the promoter regions of
CT-antigen genes showed a gradual decrease in methylation
density with increasing time of incubation (Fig. 2f and
Supplementary Fig. 8). These data support the theory that 5-
aza-CdR-induced derepression of CT antigens is mediated via
demethylation of the corresponding gene promoters.
Generation of CTL and NK-cell responses. With the successful
derepression of CT antigens in TH-enriched populations of acti-
vated lymphocytes, we next used these cells as antigen-presenting
cells for in vitro immunization. Incubation of autologous PBLs
with 5-aza-CdR-treated cells led to intensive cell proliferation
after 9-11 days. The resulting cell cultures consisted of two
dominant subpopulations; NK (CD56+ CD3−) and CD3+ T cells
(predominantly CD8+ T cells) (Fig. 3a). Interestingly, both sub-
populations were characterized by a high expression of CD62L,
and a signiﬁcant proportion of CD3+ T cells expressed CD27
(Fig. 3a). The CD3+ T cells expressed CD45RO and pre-
dominantly αβ-TcR (relative to γδ-TcR; Supplementary Table 2).
A large proportion of the NK cells expressed CD16 (Supple-
mentary Table 2). Cultivation of 5-aza-CdR-treated cells alone for
11 days did not result in an increase in cell number, and
autologous PBLs grown in the absence of 5-aza-CdR-treated cells
signiﬁcantly decreased in number (Supplementary Fig. 9).
To investigate whether the immunization procedure resulted in
clonal expansion of T cells, we employed comparative TCR
clonotype mapping. This technique utilizes the fact that
clonotypic TCR transcripts have no junctional diversity and
therefore can be resolved as distinct bands by denaturing gradient
gel electrophoresis (DGGE)22. Analysis of untreated PBLs from
donors rarely revealed distinct bands, consistent with a polyclonal
TCR repertoire. In contrast, analysis of lymphocytes expanded
upon co-culture with 5-aza-CdR-treated cells showed the
presence of multiple clonotypic TCR transcripts, ranging from
2 to >10 for each BV family (Fig. 3b).
Both NK cells and T cells can induce lysis of tumor cells, but
via different mechanisms. Lysis by T cells requires recognition of
an antigenic peptide-MHC class I complex on the surface of
target cells and is usually associated with the production of
cytokines such as IFN-γ and TNF-α. Unseparated cytotoxic
lymphocytes did not interact with untreated autologous TH cells,
whereas they did recognize 5-aza-CdR-treated TH cells (Supple-
mentary Fig. 10A). To test the activity of the T-cell component of
cytotoxic lymphocytes prepared from the blood of healthy
donors, we incubated CD56-depleted cells (hereinafter referred
to as CTLs) with autologous 5-aza-CdR-treated TH cells. As
shown in Supplementary Fig. 10B, this led to an increase in the
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Fig. 1 Fully mature DCs induce lymphocyte proliferation and enrichment for TH cells. a Flow-cytometric analysis of the expression of CD40, CD80, CD83
and CD86 on the DCs used for stimulation of lymphocyte proliferation. b PBLs from two healthy donors cultured in the presence or absence of fully mature
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production of IFN-γ, suggesting that the CTLs recognize the
antigen-presenting cells used for immunization. This effect could
be partially blocked by an MHC class I-speciﬁc antibody
(Supplementary Fig. 11). Residual anti-T cell activity in these
cultures may be due to the generation of autoreactive CD4+ cells
in response to 5-aza-CdR treatment, as previously reported23.
We next incubated CTLs with human breast cancer cell lines
and immortalized melanocytes (MEL-ST). Induction of cytokine
release by CTLs after contact with cancer cells was observed in an
HLA class I-restricted manner, whereas only minimal production
of cytokines was seen after contact with immortilized melanocytes
(Supplementary Fig. 12). Furthermore, the production of IFN-γ
could be blocked by an HLA class I-speciﬁc antibody (Supple-
mentary Fig. 13). Dose-dependent elimination of breast cancer
and glioblastoma cells by CTLs was demonstrated using a
sulforhodamine-based assay (Fig. 3c) and by real-time cell
analysis (Supplementary Fig. 14). Of note, generation of tumor-
reactive T cells was dependent on incubation with 5-aza-Cdr-
treated cells; no tumor reactivity was observed in cultures grown
in the absence of any stimulator cells (Supplementary Fig. 15).
Although 5-aza-Cdr-induced CT antigen expression in both
CD4+ and CD8+ cells (Supplementary Fig. 5), CD4+ cells were
the most efﬁcient stimulatory cells in terms of the number of
lymphocytes generated (Supplementary Table 3). To further
investigate tumor speciﬁcity, we incubated cells from a human
breast cancer biopsy with cytotoxic lymphocytes prepared from
the same patient’s blood. As shown in Supplementary Fig. 16,
cytotoxicity was induced in the tumor cells, but not in the normal
cells in the same culture.
Target recognition. To evaluate the antigen speciﬁcity of CTLs
generated by exposure to 5-aza-CdR-treated TH cells, we devel-
oped a functional assay using MEL-ST cells transduced with each
of six CT antigens (MAGE-A1, MAGE-A3, MAGE-A10, CTCFL,
GAGE-12, and CTAG1). Lytic activity against cells expressing
single antigens was demonstrated; however, the number and
proﬁle of antigens recognized varied among donors, with MAGE-
A10 and CTAG1 being the most commonly recognized targets
(Fig. 3d, Supplementary Table 4). The speciﬁcity of the immune
reaction was conﬁrmed by ELISPOT analysis using immunodo-
minant HLA-A2-restricted MAGE-A10 and CTAG1 epitopes
(Fig. 3e).
A phase 1 study in late-stage GBM. Adoptive transfer of cyto-
toxic lymphocytes was next tested in a phase 1 trial of late-stage
GBM. Between September 2011 and November 2012, a total of 25
patients with radiologically conﬁrmed recurrent GBM were
enrolled into the study. The baseline characteristics of these
patients are presented in Supplementary Table 5, including
information on ﬁrst and second-line treatments. Apart from
prednisolone, the patients received no other treatment for their
GBM during the present trial. Data on immunohistochemical
analysis of expression of selected CT antigens in diagnostic tumor
biopsies are shown in Supplementary Fig. 17 and Supplementary
Table 6. The protocol for generating cytotoxic lymphocytes used
in the clinical trial is summarized in Fig. 3f. Induction of MAGE-
antigen expression by 5-aza-CdR in TH cells from these patients,
used as a marker of successful DNA demethylation, is shown in
Supplementary Table 7. We did not detect expression of any of
these CT antigens in untreated lymphocytes.
The trial had two parts. The ﬁrst comprised three rounds of
treatment with cytotoxic lymphocytes (freshly-prepared from
repeated blood draws; median, 6.8 × 107 cells per treatment;
Supplementary Table 8) at 4–5 week intervals without prior
lymphodepletion, and evaluation after 20 weeks. In the second
part, patients compliant after the 20-week study period received
continued treatment with ad hoc injections of cytotoxic
lymphocytes.
Homing to tumor: We ﬁrst used scintigraphy to investigate the
ability of therapeutic cells to home to the tumor site. Cells
(median 30 × 106; range 1–100 × 106) were labeled with 111In-
tropolone, and radioactive accumulation in the brain was
measured 24 h after injection using single-photon emission
computed tomography/computed tomography (SPECT/CT) ima-
ging. Scintigraphic examination was performed in 15 patients
during the ﬁrst round of treatment, with repeat examination in
six of these patients during the second round of treatment.
Radioactive foci in the brain were observed in 14 of the 15
patients and in 20 out of the 21 individual examinations. Of 23
radioactive foci detected, 20 were located at the tumor site
(Fig. 4). As a control, we performed scintigraphic examination in
six patients before the ﬁrst round of treatment using 111In-
tropolone-labeled, non-activated leukocytes (median 4.0 × 108
cells; range 1.7–6.0 × 108 cells). One patient showed focal
accumulation in the brain corresponding to part of the tumor.
No radioactive uptake in the brain was observed in the ﬁve other
patients receiving non-activated leukocytes.
Safety: During the 4-week period from the ﬁrst blood donation
to the ﬁrst intravenous injection of therapeutic cells, two patients
were withdrawn from the study because of disease progression.
Among the 23 patients who received at least one round of
treatment, 32 adverse events were reported in 19 patients (Sup-
plementary Table 9), and 23 serious adverse events were reported
in 17 patients (Supplementary Table 10). All events were
considered the result of tumor progression and unrelated to
Patient 3Patient 1
MRI
Cytotoxic
lymphocyte
scintigraphy
Leukocyte
scintigraphy
Fig. 4 Homing of cytotoxic lymphocytes to the tumor site. The brain tumors
are depicted on the MRI (upper panel). Cytotoxic lymphocyte scintigraphy
(second panel) shows true positive foci with 3.1 and 1.9 times higher uptake
of radiolabeled cells in the brain tumor than in the contralateral normal
background area of Patients 1 and 3, respectively. Baseline leukocyte
scintigraphy is normal with no focal accumulation of radiolabeled cells in
the tumor of either patient (lower panel). In Patient 1, discrete leukocyte
accumulation is seen in the nose compatible with slight inﬂammation
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treatment. Nevertheless, because of the localization of the tumor
in the brain, it cannot be excluded that some neurological
symptoms (e.g., nausea, epilepsy, aphasia and transient paralysis)
might be caused or aggravated by treatment-induced inﬂamma-
tory responses.
Clinical activity: The ﬂow of the study is shown in
Supplementary Fig. 18. In total 10 of the 25 patients received
all three scheduled rounds of treatment and were alive at the
20-week evaluation. The remaining 15 patients died from
continued progressive disease before (n= 14) or immediately
after (n= 1) the 20-week evaluation, having received no
(n= 2), one (n= 9) or two (n= 4) rounds of treatment. Three
patients who received three rounds of treatment could not be
evaluated with respect to antitumor response after 20 weeks;
one because of severe compliance problems due to a previously
known respiratory insufﬁciency (Patient 14), and two because
of non-compliance due to tumor progression (Patients 9 and
24).
Treatment-induced changes in the numbers of peripheral
blood leukocytes were evaluated using data obtained immediately
before and 1–2 days after injection of cytotoxic lymphocytes.
Overall, each of the three injections of cytotoxic lymphocytes was
accompanied by a transient increase in lymphocyte counts and a
transient decrease in neutrophil counts, whereas there were no
signiﬁcant changes in total leukocyte counts (Supplementary
Fig. 19).
During the 20-week study period (130–150 days from
baseline), three patients showed decreases in tumor size of,
respectively, 18% (at 63 days; Patient 14), 28% (at 131 days;
Patient 6), and 31% (at 142 days; Patient 3) as assessed by MRI.
Two patients initially showed increases in tumor size of 138% (at
36 days; Patient 5) and 238% (at 121 days; Patient 20;
Supplementary Fig. 20), respectively, and stabilization thereafter
(Fig. 5).
Under approved compassionate use, seven patients who were
compliant after the 20-week study period received 1–18
additional lymphocyte injections until death or non-compliance
(Supplementary Table 11). MRI measurements were obtained in
connection with the in-hospital treatment with therapeutic cells.
One patient (Patient 5) showed stable disease on MRI but died
171 days after the ﬁrst injection, one month after an ultrasound
investigation had identiﬁed multiple metastases to the liver,
consistent with adenocarcinoma (no biopsy was performed due to
the poor clinical condition of the patient). Three patients
(Patients 2, 18 and 24) showed tumor progression on MRI and
underwent further surgical tumor debulking but died due to
disease progression, 440, 267 and 164 days after the ﬁrst
lymphocyte injection, respectively.
The three remaining patients (3, 6, and 20) showed decreases
in tumor size of, respectively, 86% (at day 668), 63% (at day 418),
and 100% (at day 549) as assessed by MRI (Fig. 5). The
corresponding assessments by FET-PET showed marked reduc-
tions in metabolically active tumor volumes in Patients 3 (Fig. 6)
and 6, from 65 to 32.8 cm3 and from 15.4 to 2.8 cm3, respectively.
In patient 20, the metabolically active tumor volume was 24 cm3
at enrollment, with an increase to 43 cm3 at day 261 and then a
decrease to 29.5 cm3 at day 791 (Supplementary Fig. 20). These
three patients all experienced improvements in cognitive and
motor functions. It is noteworthy that one of these patients
(Patient 3) had no increase in tumor size during a period of
nearly nine months between two injections of cytotoxic
lymphocytes. There were no adverse events observed in any of
the seven patients receiving continued treatment.
Patient 3 died 717 days after initiation of treatment from a
small metastatic lesion in the brainstem (visualized on MRI;
autopsy could not be performed). Patient 6 died from an
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Fig. 5 Treatment responses in 10 patients with relapsed GBM. All patients
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size of the contrast-enhancing tumor on MRI. In general, the MRI
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with therapeutic cells
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Fig. 6 Treatment response in Patient 3. This 76-year-old patient had a
bilateral GBM tumor and was treated with radiation and concomitant
temozolomide, with tumor progression four months into the temozolomide
regimen. The patient received a total of eight injections of autologous
cytotoxic lymphocytes, and stable disease was achieved within one month
after the ﬁrst injection. The MR images (top panel) illustrate a continuous
reduction in size of the contrast-enhancing lesion by 63% over a course of
542 days. The middle and lower panels represent FET-PET images at two
different levels of the brain, showing a 50% reduction in metabolically
active tumor volume over the course of one year. The green areas represent
the invasive parts of the tumor
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unrelated heart condition 545 days after initiation of
treatment. Post-mortem histopathological examination of the
brain from this patient using a panel of immunohistochemical
markers (the proliferation marker Ki-67, the stem-cell marker
Nestin and the tumor markers Olig2, MAP2, and p53) revealed
complete absence of cancer cells at the previous tumor site, in
the surrounding brain parenchyma and in the contralateral
hemisphere. Staining for CD68 and GFA demonstrated the
presence of cells of the macrophage lineage and gliosis with
hypertrophic glial cells (Fig. 7). Staining for CD8 revealed rare
scattered T cells with occasional clusters around a necrotic
cavity at the previous tumor location (Supplementary Fig. 21).
Patient 20 experienced relapse and died 1384 days after
initiation of treatment (visualized on MRI; autopsy could not
be performed).
Discussion
We report a novel approach to cancer immunotherapy based on
the adoptive transfer of cytotoxic lymphocytes with speciﬁcity for
antigens induced by DNA demethylation. The biological rationale
for this therapeutic strategy was to target the widest possible
repertoire of CT antigens, as numerous studies reported great
variation in expression of individual CT antigens across tumor
types and stages, as well as within tumors7. We posited that
induction of an immune response against multiple CT antigens
could increase therapeutic efﬁcacy and decrease the risk of
resistance development relative to single-target therapies. The
technical rationale was to induce expression of endogenous CT
antigens in autologous antigen-presenting TH cells by pharma-
cological demethylation. The key discovery that made this
approach feasible was the ability to utilize autologous fully mature
DCs to induce non-speciﬁc lymphocyte proliferation ex vivo and
enrich for TH cells. After induction of CT-antigen expression by
DNA demethylation, these TH cells could readily be used as
antigen-presenting cells.
Exposure of PBLs to DNA-demethylated TH cells led to the
generation of tumor-reactive CTLs and NK cells. Since DNA
demethylation can, in theory, induce expression of hundreds of
CT antigens7, CTLs targeting a speciﬁc CT antigen would be
expected to represent only a small fraction of the total CTL
population. Still, speciﬁc lysis was induced not only in tumor cells
expressing multiple CT antigens, but also in primary cells
expressing single CT antigens. It is noteworthy that the T cell
precursor frequencies for two of the recognized antigens in our
testing panel, MAGE-A10 and CTAG1, were reported to be sig-
niﬁcantly higher in healthy donors compared to other investi-
gated CT antigens24, 25. It is well known that one of the leading
factors for the induction of an immune response against a speciﬁc
antigen is the T cell precursor frequency26. Hence, our results
provide proof-of-principle that it is possible to generate a poly-
valent response to a variety of CT antigens, provided that CTL
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Fig. 7 Treatment response in Patient 6. a Immunohistochemical analysis of Ki-67, Nestin and GBM markers in biopsies obtained at diagnosis (tumor) and
autopsy (previous tumor location), × 200 objective; scale bar= 50 µm. b Low-magniﬁcation ( × 12.5 objective; scale bar= 1 mm) overview of the affected
brain region from the autopsy specimen (HE) and immunohistochemical analysis of the macrophage lineage marker CD68 and the astrocyte marker GFA,
× 400 objective; scale bar= 25 µm. The previous tumor location area analyzed by immunohistochemistry, including the necrotic cavity, is indicated by
dashed lines
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precursors are present at certain levels. Lack of reproducible
detection of immune responses against other tested CT antigens
probably reﬂects a low frequency of their respective precursors,
and does not exclude generation of a CTL response against these
antigens, albeit at low levels. One might expect that, after multiple
rounds of treatment with cytotoxic lymphocytes in the same
patient, the proportions of CTLs originally present at low fre-
quencies would increase and hence broaden and strengthen the
immune response against tumor cells.
Current protocols for ex vivo expansion of therapeutic T cells
tend to drive these cells into a state of high differentiation and
replicative exhaustion27. Studies in various animal models have
shown that, despite their ability to effectively kill tumor cells,
highly differentiated effector memory T cells and terminally dif-
ferentiated effector T cells have low antitumor activity compared
with less differentiated central memory T cells28, 29. This loss of
therapeutic potential may be attributed at least partially to the
loss of expression of CD27, a molecule required for long-term T-
cell survival30, 31, and CD62L, a cell adhesion molecule that allows
lymphocytes to enter secondary lymphoid tissues by transen-
dothelial migration via high endothelial venules and hence is
critical for the generation of long-lived pools of memory cells32.
Several lines of evidence suggest that CD62L expression may also
be a major determinant of the ability of lymphocytes to inﬁltrate
tumors28, 33. The two major cell populations generated by the
immunization protocol described herein, CD8+ T cells and NK
cells, both expressed CD62L, consistent with an early differ-
entiation state34, 35, and with the potential to inﬁltrate tumors.
Indeed, in our study, scintigraphic analysis demonstrated homing
of the injected cytotoxic lymphocytes to the tumor site. Whether
the CD8+ T component, by virtue of its phenotype (including the
expression of CD27), is capable of inducing a long-lasting
immune response, thus obviating the need for repeated injections,
is a topic for future studies.
The median survival after diagnosis of GBM is 14.6 months,
making it one of the most lethal forms of cancer and one of the
most challenging to treat10, 11. In the present study, disease
control was achieved in ﬁve of ten patients receiving the three
scheduled injections of therapeutic cells, with long-term tumor
regression in three of these patients who were all in the terminal
phase of their disease with rapidly growing tumors. The lack of
objective responses in the majority of our patients should be
interpreted in the context of their poor clinical condition, with a
life expectancy of <6 months. Similar to several other forms of
immunotherapy36, a disadvantage of our approach may be the
slow kinetics of the induced antitumor response. Indeed, in three
of the responding patients, disease stabilization became manifest
several months after the ﬁrst injection of cytotoxic lymphocytes,
with initial increases in tumor burden. Hence, in many patients
with relapsed GBM and rapid progression, the disease may
become fatal before an efﬁcient antitumor response can be gen-
erated. Alternatively, the lack of response may have been the
result of tumor-mediated immune evasion mechanisms37 or the
lack of CT-antigen expression by tumor cells.
The extent and type of side effects associated with cell-based
immunotherapeutic cancer therapies depend on the targeted
antigens. For example, depigmentation due to autoimmune
melanocyte destruction is a common side effect of therapies
targeting melanocyte differentiation antigens such as MART-1
and gp10038, and targeting of CD19 (a B cell-speciﬁc antigen) in
leukemias results in conditions associated with loss of normal B
cells, including lymphopenia and degammaglobulinemia5, 39. Of
particular relevance to this study, severe treatment-induced car-
diovascular and neurological toxicity has been observed in
patients treated with autologous T cells genetically engineered to
express a TCR targeting the widely-expressed CT antigen,
MAGE-A34, 40. These adverse effects were likely due to off-target
reactivity of the genetically engineered TCRs used in these stu-
dies, which were afﬁnity matured to achieve an avidity in excess
of the natural TCR. Our approach did not involve any mod-
iﬁcation of TCRs, which may explain the absence of toxic, allergic
or autoimmune reactions despite theoretically targeting a broad
spectrum of CT antigens. Nevertheless, it cannot be excluded that
some of the neurological symptoms observed in our GBM trial
could be caused by treatment-induced inﬂammatory responses in
the brain, elicited by on-target on-tumor effects of the therapeutic
cells.
In summary, we show that adoptive transfer of lymphocytes
with reactivity to antigens induced by DNA demethylation is
a potential approach to anticancer immunotherapy. This mini-
mally invasive strategy may overcome important limitations of
current immunotherapies in terms of antigen coverage and dif-
ferentiation state of therapeutic lymphocytes, hence providing a
general strategy for treatment of a wide range of human cancers,
potentially in combination with checkpoint inhibitors to remove
T-cell inhibition. For tumors with low expression of CT antigens,
immunogenicity may be enhanced by systemic treatment with
DNA-demethylating drugs to selectively upregulate CT-antigen
expression in the tumor cells prior to immunotherapy41, 42.
Provided that the induced immune response is persistent and has
no long-term adverse effects in healthy persons, the present
approach may also open new possibilities for cancer prevention.
Patients and methods
Patients. The study was performed at the department of Neurosurgery, Rig-
shospitalet, Copenhagen, Denmark. Inclusion criteria were radiologically con-
ﬁrmed relapsed GBM on magnetic resonance imaging (MRI) and a Karnofsky
performance score of >50% in patients >18 years of age. Exclusion criteria were
blood hemoglobin <6 mM, positive test for HIV, hepatitis B and C and syphilis.
Informed consent was obtained from all patients. The study was conducted in
accordance with the Declaration of Helsinki and approved by The Committee on
Biomedical Research Ethics of the Capital Region of Denmark (H-1-2011-068).
Study design and treatment. In this open, prospective phase 1 study, patients
with relapsed late-stage GBM received a total of three intravenous injections
(injection site: peripheral vein of the arm or hand) of cytotoxic lymphocytes every
4–5 weeks and were monitored during a 1–2 day hospitalization period. For each
patient, successive batches of cytotoxic lymphocytes were prepared from freshly
drawn blood. Immediately prior to the ﬁrst injection, the prednisolone dose was set
at a maximum of 37.5 mg/day; however, any subsequent symptoms related to
increased tumor edema were treated ad hoc with higher doses. During the trial with
cytotoxic lymphocytes, the patients received no other treatment for their GBM
than prednisolone. All patients included in the study were evaluated for safety
(primary endpoint). Patients who were compliant 6 weeks following the ﬁrst
injection of cytotoxic lymphocytes (n= 14) were evaluated for safety and tumor
control (secondary endpoint). The protocol had an overall duration of 20 weeks
from the initial blood donation to the last visit. The actual treatment started in
week 5 with the ﬁrst injection of cytotoxic lymphocytes. After the 20-week study
period, patients who were compliant were given 1–18 additional injections of
cytotoxic lymphocytes on a compassionate basis.
Total numbers of leukocytes, lymphocytes and neutrophils in patient blood
were measured immediately before and 1-2 days after injection of cytotoxic
lymphocytes. Disease assessment was performed by MRI and O-(2-[18F]
ﬂuoroethyl)-L-tyrosine positron emission tomography (FET-PET) (Supplementary
Methods). Homing of radiolabeled cells was analyzed by scintigraphy
(Supplementary Methods). Safety and tolerability assessments are described in
Supplementary Methods. The present clinical trial is listed on-line at https://
eudract.ema.europa.eu as protocol EudraCT Number 2011-002180-22, and at
http://www.clinicaltrials.gov with identiﬁer NCT01588769, and was monitored
according to Good Clinical Practice by an independent unit in Copenhagen.
Cell lines. Breast cancer cell lines MDA-MB-231, T47D, CAMA-1 and MCF-7 and
the glioblastoma cell line U-87 were purchased from ATCC (Manassas, VA). FM3
and FM3.29 melanoma cell lines have been previously described43. All cell lines
were tested for mycoplasma contamination. Cells were cultured in RPMI 1640
medium supplemented with 10% FCS. Data on CT-antigen expression in these cell
lines are provided in Supplementary Table 12.
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Preparation of cytotoxic lymphocytes. The standard 26-day procedure for pre-
paration of cytotoxic lymphocytes is outlined in Fig. 3f and consists of the fol-
lowing steps:
Preparation of mature dendritic cells (DCs): Preparation of mature dendritic
cells was essentially as described44. Mononuclear cells were isolated as described44.
After last washing, cells were re-suspended in cold DPBS and counted using the
model Z2 Coulter Counter. Monocyte concentration was determined by gating the
corresponding cell peaks. Generation of DCs was performed in T225 tissue culture
ﬂasks pre-treated with 30 ml of 5% human AB serum in RPMI 1640. After removal
of pre-treatment medium, 40 ml of a cell suspension containing 5 × 107 monocytes
in AIM-V medium were added. After 30 min of incubation at 37 °C, non-adherent
lymphocytes were collected, adherent monocytes rinsed twice with pre-warmed
RPMI 1640 medium and further cultured in AIM-V medium. The collected
lymphocytes were frozen in several aliquots. After overnight incubation (day 1),
and at day 3, GM-CSF and IL-4 (both from Gentaur, Belgium, or CellGenix,
Germany) were added to the cells at ﬁnal concentrations of 100 ng/ml and 25 ng/
ml, respectively. At day 4, IL-1β, IL-6, TNF-α (all from Gentaur) and PGE2
(Sigma) were added at ﬁnal concentrations of 10 ng/ml, 1000 IU/ml, 10 ng/ml and
0.2 µg/ml, respectively. At day 6, non-adherent cells were harvested, counted and
used for our experiment, and the remainder were frozen in aliquots of 2–3 × 106
cells.
Induction of CD4+ cell proliferation and 5-aza-CdR treatment: A mixture of
thawed non-adherent lymphocytes and DCs (in 10:1 ratio) was incubated in AIM-
V medium containing 1% autologous serum. At day 1, IL-2 was added at ﬁnal
concentration of 25 IU/ml. Fresh medium and IL-2 were added at days 4 and 6. At
day 7, cells were collected, counted, washed, resuspended in fresh medium, and,
after addition of 150 IU/ml of IL-2 and 10 µM 5-aza-CdR, cultured for 2 days.
Induction of cytotoxic lymphocytes: A mixture of 5-aza-CdR-treated cells and
thawed non-adherent lymphocytes (0.5 × 106/ml each) was incubated in AIM-V
medium containing 2% autologous serum. After 2 days of incubation, IL-2 was
added at a ﬁnal concentration of 25 IU/ml. Fresh medium and IL-2 were added at
days 5, 7, and 9. At day 11, a portion of the cells was used for ﬂow cytometry and,
after release of the product, cells were prepared for injection by washing and
placing into a syringe in 21 ml of Plasma-Lyte (Baxter International, Deerﬁeld, IL)
with the addition of 5% autologous serum.
Flow cytometry. For determination of surface expression of different markers on
the cells, we used the directly conjugated antibodies listed in Supplementary
Table 13. The recommended isotypic controls were used for the phenotyping of the
cells. The cell samples were analyzed using FC500 MPL Flow Cytometer (Beckman
Coulter) and the CXP analytical software (Beckman Coulter).
Cytokine production. CD56-depleted cells were isolated from cytotoxic lympho-
cytes prepared from the blood of HLA-A2+ donors using CD56 Microbeads
(Miltenyi Biotec) according to the manufacturer’s instructions. After isolation,
lymphocytes were washed once, re-suspended at a concentration of 5 × 105/ml, and
added to a panel of breast cancer cell lines. Tumor cells (2 × 104) were seeded in a
48-well plate in 0.5 ml of RPMI-1640 medium with addition of 10% FCS one day
before the test. 0.5 ml of the suspension of isolated lymphocytes containing 2.5 ×
105 cells was added to the tumor cells. Cells were cultured together for 18–20 h.
Production of IFN-γ and TNF-α in the culture supernatant was measured by
ELISA (see below).
Sulforhodamine B assay. Cell monolayers were incubated with cytotoxic lym-
phocytes for 24 h. The lymphocytes were then removed from the wells by gravity
sedimentation. Brieﬂy, the wells were ﬁlled with DPBS, sealed and turned upside-
down for 20 min, after which the sealer was detached without changing the plate’s
position, and excess liquid removed by gentle blotting on a paper towel. Adherent
cells were ﬁxed, stained with 0.06% Sulforhodamine B (SRB) and processed
according to a previously described version45 of the SRB assay46. The dye was
extracted and absorbance measured at 550 nm for cultures incubated with or
without lymphocytes. The survival index was determined as the ratio between these
cultures, with the control culture (without lymphocytes) set as 100%.
Cytokine ELISA. Concentrations of IL-12p70, IFN-γ, and TNF-α in cell culture
supernatants were measured by sandwich ELISA using appropriate “Ready-Set-Go”
kits (eBioscience). The procedure was essentially as recommended by the manu-
facturer, except that when measuring IL-12p70, the standards and samples in
triplicates were incubated with detection antibodies at room temperature for 2 h
followed by overnight incubation at 4 °C.
Real-time monitoring of cell viability. Cytolytic activity of lymphocytes was
monitored in real-time cytotoxicity assays using the iCELLigence system (ACEA
Biosciences, San Diego, CA, USA). Tumor cells were seeded at a density of 3 × 104
cells per well in a total volume of 400 μL of RPMI 1640 medium with 10% FCS.
After 20-24 h initial incubation, 100 µl of culture medium were removed, and 0.2 ×
106 lymphocytes were added in 200 µl of AIM-V medium. Killing of tumor cells
was associated with a decrease in cell impedance (measured as Cell Index), and was
monitored every 15 min for 20–25 h and presented as normalized Cell Index.
Immunohistochemistry. Surgical specimens were routinely formalin-ﬁxed,
parafﬁn-embedded and sectioned at 4 µm thickness. Immunohistochemical stain-
ing was performed on a BenchMark ULTRA IHC Staining module using OptiView
DAB/Ventana, Roche, according to OptiView DAB IHC v5 protocol. Sections were
ﬁrst deparafﬁnized. Antigen retrieval was achieved by incubating the sections at
100 °C, pH 8.5 for 32 min. The sections were incubated in hydrogen peroxide for
peroxidase inhibition, followed by incubation with the primary antibody. The
antibodies used are listed in Supplementary Table 13.
Transduction of immortalized melanocytes. Immortalized human melanocytes,
MEL-ST ([47]; a gift from R.A. Weinberg, Whitehead Institute for Biomedical
Research and Massachusetts Institute of Technology, Cambridge, Massachusetts,
USA), were transduced with lentivirus to express CT antigens. Six CT-antigen open
reading frames (MAGE-A1, MAGE-A3, MAGE-A10, CTCFL, GAGE12, and
CTAG1) were cloned from testes RNA into a lentiviral expression vector (CD513B-1,
System Biosciences). As controls, we used empty vector. The vectors were packed
in HEK293T cells into lentiviral particles, which were used to transduce the
immortalized melanocytes. Four days after transduction, the cells were selected
with 0.25 µg/ml puromycin for one week. The vector contains the gene encoding
the green ﬂuorescent protein (GFP), and successful transduction was conﬁrmed in
a ﬂuorescence microscope or with ﬂow cytometry. The cells were grown in DMEM
medium supplemented with 5% FBS.
ELISPOT analysis. Autologous mature dendritic cells were seeded into 24-well
plates (105 cells per well) in 1 ml of AIM-V medium supplemented with 2% of
autologous serum. HLA-A2-restricted peptides from CTAG1 (p157-165,
SLLMWITQC, IBA, Goettingen, Germany) and MAGEA10 (p254-262, GLYDG-
MEHL, KJ Ross-Petersen ApS, Copenhagen, Denmark) were added at a con-
centration of 20 µg/ml, and after 30 min incubation at room temperature,
autologous CD56-negative cells were added. After 48 h, IL-2 (50 IU/ml) was added
to the culture wells and cells were cultured for additional 5 days. IFN-γ ELISPOT
assays were performed in 96-well precoated plates using the 3420-4APW-2 Human
IFN-γ ELISpotPLUS Kit (ALP) (MABTECH, Stockholm, Sweden). After washing
with PBS, wells were blocked with 10% FCS for 30 min. Fifty thousand CD56-
negative cells, either presensitized with peptide for 7 days (see above) or not
presensitized (cultured under the same conditions without the addition of peptides)
were added to each well in the presence or absence of peptides. After overnight
incubation, plates were processed according the manufacturer’s procedure.
Counting of spots was done automatically using the ImmunoSpot Reader (Cellular
Technologies Limited) and the ImmunoSpot 4.0 software.
RT-PCR. Total RNA was isolated from tumor cells and lymphocytes according to
protocol 148, reconstituted in RNase-free water, treated with DNase from the
Turbo-DNA-freeTM kit (Invitrogen), and reverse transcribed with SuperScript III
reverse transcriptase using random hexamers and oligo(dT24) as primers. cDNA
and DNase-treated RNA (negative control) were ampliﬁed using a block cycler and
gene-speciﬁc primers (Supplementary Table 14) for 32-35 (MAGEs) and 37-43
(GAGE3-7, CTAG1 and CTCFL) cycles under previously reported conditions49, 50.
For qPCR, total RNA was isolated using the NucleoSpin RNA Plus kit (Macherey-
Nagel), and reverse transcribed using SuperScript™ IV VILO™ Master Mix with
ezDNase™ Enzyme (Invitrogen) and random hexamers and oligo(dT24) primers.
cDNA was ampliﬁed in a LightCycler Nano (Roche) using the FastStart Essential
DNA Green Master mix (Roche) and previously described primers and condi-
tions51, except that validated primer sets for MAGEA4, MAGEA10 and CTAG1B
were VHPS-5479, VHPS-5478 and [5’-TCTCCATCAGCTCCTGTCTC-3’ and 5’-
CAAACATGTAAGCCGTCCTC-3’], respectively (Biomol). The data were nor-
malized to GAPDH expression.
TCR clonotype analysis. Clonotypic T cells were detected by RT-PCR/DGGE-
based TCR clonotype mapping, as previously described22. In brief, cDNA was
ampliﬁed using primers for TCRBV regions 1–24. For BV regions that were
expressed in both untreated PBLs and CTLs from the same donor, amplicons
were analyzed in a 6% polyacrylamide, 20–80% denaturant gel (100% denaturant
= 7M urea and 40% formamide). The gel was run at 160 V for 4.5 h in TAE
buffer (0.04 M Tris-acetate, 0.001 M EDTA) kept at a constant temperature of
56 °C, stained with ethidium bromide, and photographed under UV
transillumination.
DNA methylation analysis. DNA was isolated from cultured cells and treated with
sodium bisulﬁte using the EZ DNA Methylation-Gold™ Kit (Zymo Research). The
methylation status of gene promoter regions was determined by methylation-
speciﬁc melting curve analysis (MS-MCA)52 using the LightCycler 2.0 (Roche) and
the FastStart DNA Master SYBR Green I Kit (Roche), and by pyrosequencing on a
PyroMark Q24 platform (Qiagen). Primer sequences are listed in Supplementary
Tables 15 and 16.
Cell-based ELISA. The procedure was essentially as described for quantiﬁcation of
gp10053 except that ELISA optical density readings obtained for two-fold serial
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dilutions of cells incubated with supernatants of the MAGE-speciﬁc 57B clone21
were corrected for unspeciﬁc binding of isotype-matched IgG1 at the same con-
centration. The optical density was measured at 630 nm for the non-terminated
reactions and at 450 nm after termination with HCl.
Immunoblotting. The total protein concentration was measured using the Pierce
BCA Protein Assay Kit (Thermo Scientiﬁc). Aliquots were lysed in Laemmli buffer,
boiled for 5 min and separated on 12% NuPAGE Bis-Tris gels in MOPS buffer
(Invitrogen). Proteins were transferred to a nitrocellulose membrane (Hybond
ECL, Amersham), blocked with 5% non-fat dry milk and 5% FCS in TBS, incu-
bated with the primary antibody (57B) overnight at 4 °C and then with HRP-
conjugated rabbit anti-mouse immunoglobulins (1:1000, Dako; Cat.no. P0260) for
1 h at room temperature. Reactive bands were visualized by Enhanced Chemilu-
minescence (ECL) detection (Amersham).
Data availability. All relevant data are available within the article and Supple-
mentary Files, or available from the authors upon request.
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